Reference : A randomized, open-label, multicenter study evaluating the efficacy of peginterferon ...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
http://hdl.handle.net/2268/71901
A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients.
English
Nevens, F. [ > > ]
Van Vlierberghe, H. [ > > ]
D'Heygere, F. [ > > ]
Delwaide, Jean mailto [Université de Liège - ULg > > Gastro-Entérologie-Hépatologie >]
Adler, M. [ > > ]
Henrion, J. [ > > ]
Lenaerts, A. [ > > ]
Hendlisz, A. [ > > ]
Michielsen, P. [ > > ]
Bastens, B. [ > > ]
Brenard, R. [ > > ]
Laureys, A. [ > > ]
2010
Acta Gastro-Enterologica Belgica
Acta Medica Belgica
73
223-228
Yes (verified by ORBi)
International
0001-5644
Bruxelles
Belgique
[en] Background/Aims : A large multicenter trial to compare the
efficacy of peginterferon alfa-2a with interferon alfa-2a, in combination
with ribavirin, in chronic hepatitis C patients. Efficacy data
for prior relapsers are reported because treatment recommendations
for this patient population are not well defined.
Patients and methods : This study was a multicenter, prospective,
randomized clinical trial. The primary efficacy endpoint was sustained
virologic response in naïve patients (n = 348) and relapsers
(n = 95).
Results : Sustained virologic response rates were similar in naïve
patients and relapsers, both for non-pegylated and pegylated interferon
(respectively 27 and 26% and 54 and 43%). Pegylated interferon
given for 48 weeks did not improved the relapse rate : 15.9
and 27.3% for non-pegylated and 16.7 and 30.4% for pegylated
interferon, naïve vs relapsers respectively. Stepwise logistic regression
analysis revealed a significant association between slow
response (detectable HCV RNA at week 12 and undetectable at
week 24) and relapse in patients with an end-of-treatment response
(55% versus 13% respectively ; p = 0.02 ; odds ratio = 6.07).
Conclusions : This trial confirms the value of using peginter -
feron alfa-2a in both naïve and relapsed patients and provides
support for a more tailored approach to treatment for relapsers
and particulary for patients with a slow viral response. (Acta
gastro enterol. belg., 2010, 73, 223-228).
Researchers ; Professionals
http://hdl.handle.net/2268/71901

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
03-Nevens et al Bernar 1.pdfPublisher postprint120.01 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.